242 related articles for article (PubMed ID: 7741298)
1. The effect of intrinsic efficacy on opioid tolerance.
Duttaroy A; Yoburn BC
Anesthesiology; 1995 May; 82(5):1226-36. PubMed ID: 7741298
[TBL] [Abstract][Full Text] [Related]
2. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.
Paronis CA; Holtzman SG
J Pharmacol Exp Ther; 1992 Jul; 262(1):1-9. PubMed ID: 1625189
[TBL] [Abstract][Full Text] [Related]
3. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
4. Opioid receptor regulation in mice.
Yoburn BC; Billings B; Duttaroy A
J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
[TBL] [Abstract][Full Text] [Related]
5. Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse.
Madia PA; Dighe SV; Sirohi S; Walker EA; Yoburn BC
Psychopharmacology (Berl); 2009 Dec; 207(3):413-22. PubMed ID: 19816677
[TBL] [Abstract][Full Text] [Related]
6. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice.
Shen KF; Crain SM
Brain Res; 1997 May; 757(2):176-90. PubMed ID: 9200746
[TBL] [Abstract][Full Text] [Related]
7. Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists.
Paronis CA; Holtzman SG
Psychopharmacology (Berl); 1994 May; 114(4):601-10. PubMed ID: 7855222
[TBL] [Abstract][Full Text] [Related]
8. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
[TBL] [Abstract][Full Text] [Related]
9. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
Stafford K; Gomes AB; Shen J; Yoburn BC
Pharmacol Biochem Behav; 2001; 69(1-2):233-7. PubMed ID: 11420091
[TBL] [Abstract][Full Text] [Related]
10. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
[TBL] [Abstract][Full Text] [Related]
11. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats.
Walker EA; Young AM
Psychopharmacology (Berl); 2001 Mar; 154(2):131-42. PubMed ID: 11314675
[TBL] [Abstract][Full Text] [Related]
12. Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
Chan KW; Duttory A; Yoburn BC
Eur J Pharmacol; 1997 Jan; 319(2-3):225-8. PubMed ID: 9042594
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antinociceptive actions and tolerance development produced by morphine-fentanyl coadministration: correlation with μ-opioid receptor internalization.
Silva-Moreno A; Gonzalez-Espinosa C; León-Olea M; Cruz SL
Eur J Pharmacol; 2012 Jan; 674(2-3):239-47. PubMed ID: 22079772
[TBL] [Abstract][Full Text] [Related]
14. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
Kumar P; Sunkaraneni S; Sirohi S; Dighe SV; Walker EA; Yoburn BC
Eur J Pharmacol; 2008 Nov; 597(1-3):39-45. PubMed ID: 18789923
[TBL] [Abstract][Full Text] [Related]
15. Spinal and supraspinal effects of pertussis toxin on opioid analgesia.
Shah S; Duttaroy A; Davis T; Yoburn BC
Pharmacol Biochem Behav; 1994 Nov; 49(3):773-6. PubMed ID: 7862737
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude.
Allen RM; Dykstra LA
J Pharmacol Exp Ther; 2000 Dec; 295(3):1012-21. PubMed ID: 11082436
[TBL] [Abstract][Full Text] [Related]
17. Differences in the characteristics of tolerance to μ-opioid receptor agonists in the colon from wild type and β-arrestin2 knockout mice.
Maguma HT; Dewey WL; Akbarali HI
Eur J Pharmacol; 2012 Jun; 685(1-3):133-40. PubMed ID: 22521552
[TBL] [Abstract][Full Text] [Related]
18. Continuous morphine produces more tolerance than intermittent or acute treatment.
Dighe SV; Madia PA; Sirohi S; Yoburn BC
Pharmacol Biochem Behav; 2009 May; 92(3):537-42. PubMed ID: 19248799
[TBL] [Abstract][Full Text] [Related]
19. Differential analgesic cross-tolerance to morphine between lipophilic and hydrophilic narcotic agonists.
Paktor J; Vaught JL
Life Sci; 1984 Jan; 34(1):13-21. PubMed ID: 6141509
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the potency and intrinsic activity of systemic versus intrathecal opioids in rats.
Abram SE; Mampilly GA; Milosavljevic D
Anesthesiology; 1997 Jul; 87(1):127-34; discussion 27A-29A. PubMed ID: 9232143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
